Refine
Document Type
- Doctoral Thesis (6)
Language
- English (6)
Has Fulltext
- yes (6)
Is part of the Bibliography
- no (6)
Keywords
- ACKR (1)
- Eosinophils (1)
- GPCR (1)
- Immunbiology (1)
- Immune cells (1)
- Inflammation (1)
- Macrophages (1)
- Pharmacology (1)
Institute
- Medizin (4)
- Biochemie, Chemie und Pharmazie (1)
- Biowissenschaften (1)
Introduction: The involvement of platelets in various diseases has been increasingly recognized in the recent decades. This contribution is believed to involve platelet secretion and formation of reactive microparticles. Platelets contain two functionally important forms of vesicles, alpha and dense granules, which are secreted upon activation of platelets. Alpha granules incorporate larger molecules such as adhesive proteins, e.g. P-selectin, vWF and fibrinogen; chemokines like PF4 and RANTES and growth hormones like VEGF and PDGF are among the most important proteins attributed to the involvement of platelets in pathological conditions. In contrast, dense granules contain small molecules like ADP, ATP, serotonin and histamine, and they are more rapidly and completely secreted than alpha granules. Like in all secreting cells, regulated exocytosis in platelets is mediated by “zippering” of three different classes of SNARE proteins. The subtypes of these proteins found to be involved in platelet secretion are SNAP-23, syntaxin-2 and -4 and VAMP-3 and -8. Apart from SNARE proteins, other conserved proteins influencing exocytosis by e.g. acting on SNARE proteins have been described, one of the most important ones being Munc13. Platelets contribute to the progression of atherosclerosis by local deposition of inflammatory mediators like PF4, RANTES and CD40L, which leads to enhanced leukocyte recruitment and plaque formation. In 1865, Armand Trousseau first described the correlation between cancer and thrombotic events. Since the 1960s, an increasing number of studies have found an involvement of platelets also in the progression of cancer, especially in the formation of metastases. Platelets bind to circulating tumor cells and may shield them from NK cell attacks and shear stress. Platelets may also facilitate the interaction of tumor cells with other cell types and the vessel wall. Lastly, they may secrete molecules that influence the tumor cell phenotype and invasiveness.
Aims of this study: We sought to generate and describe genetically modified mouse lines with defective platelet secretion and to employ these mouse lines in murine models of atherosclerosis and tumor progression to study the role of platelet secretion under pathological in vivo conditions.
Results: Clostridial toxins cleave members of the SNARE protein family and can thus completely block exocytosis of neuronal and other cells. We generated three transgenic mouse lines expressing tetanus, botulinum-E or -C light chains and two transgenic mouse lines with dominant-negative mutations of SNAP-23 under the control of the platelet-specific PF4 promotor. None of these constructs was able to interfere with platelet secretion despite expression of the transgene. A functional null mutant of the only Munc13 isoform expressed in platelets, Munc13-4, showed complete lack of dense granule secretion, measured by ATP release, while alpha granule release as determined by PF4 and vWF secretion, was unaltered. Morphology, composition and adhesion of these platelets were also normal. Aggregation in response to U46619 and collagen and formation of large aggregates in flow chamber assays was attenuated. Munc13-4-deficient mice showed a severe defect in bleeding time and no formation of stable aggregates in FeCl3 thrombosis model. In response to B16 melanoma and LLC1 carcinoma cells, Munc13-4 KO platelets also showed complete abrogation of dense granule secretion, whereas alpha granule secretion and binding of platelets to tumor cells was unchanged. Interestingly, wild-type platelets, but not Munc13-4 KO platelets, enhanced transmigration of B16 and LLC1 cells through an endothelial cell layer. Exogenous ATP was able to mimic the effect of wild-type platelets and the ATP-degrading enzyme apyrase blocked platelet-mediated tumor cell transmigration. Platelets incubated with tumor cells secreted large amounts of ATP. Murine endothelial cells showed perturbed adherens junctions identified by irregular VE-cadherin staining and gap formation when incubated with supernatants from tumor cell-activated platelets as well as increased permeability under the same conditions. Addition of apyrase preserved normal endothelial morphology and function. In vivo, primary tumor growth and weight was comparable in wild-type and Munc13-4 KO mice upon B16 or LLC1 flank injection but formation of lung metastases was strongly reduced. Number, but not size of metastases was also reduced upon i.v. injection of B16 and LLC1 cells. We found P2Y2 and P2X4 receptors to be the most abundantly expressed endothelial metabotropic and ionotropic ATP receptors, respectively. Neither knock-down nor inhibition of P2X4 in endothelial cells influenced platelet-mediated transendothelial migration of B16 cells, but knock-down of P2Y2, for which no specific antagonist is available, strongly reduced plateletdependent tumor cell transmigration. When B16 melanoma cells were injected i.v. shortly after FITC-dextran (70 kDa) into wild-type mice, prominent leakage of FITC-dextran was observed three hours post-injection at extraluminal sites in the lung. In contrast, leakage into the lung parenchyma was at basal levels in Munc13-4 KO and P2Y2 KO mice after B16 cell injection. Marginal vascular leakage in Munc13-4 KO mice lacking platelet ATP secretion and in P2Y2 KO mice lacking the main endothelial ATP receptor correlated with strongly reduced extravasation of CFSE-labeled B16 melanoma cells 6 hours post-injection in these mice. Consistently, P2Y2 KO mice showed strongly reduced formation of metastases in the lung after i.v. injection of B16 or LLC1 tumor cells. Bone marrow-transplanted LDLR KO mice reconstituted with Munc13-4-deficient or wildtype bone marrow and subjected to 16 weeks of high fat diet showed no significant difference in atherosclerotic plaque formation in the aorta.
Discussion: We hereby provide a thorough analysis of a mouse line with an exclusive defect in platelet dense granule secretion, thus representing a unique genetic tool to study the role of dense granule secretion in various contexts without interfering with other platelet functions. We also provide evidence how extravasation of circulating tumor cells is facilitated by tumor cell-induced ATP release from platelets. This ATP release destabilizes endothelial barriers and facilitates tumor cell extravasation and formation of metastases in the target organ. Since metastasis is the leading cause of cancer death, pharmacological interference with endothelial P2Y2 receptor function may represent a promising therapeutic strategy.
Endothelial dysfunction plays an important role in different pathological conditions, but whether endothelial cell death contributes to the development and progression of certain pathological conditions is rather unclear. Here we found that endothelial cells undergo cell death during pathologies such as LPS-induced sepsis and in models of hindlimb, renal and cardiac ischemia-reperfusion injury. Analyses of mice lacking endothelial key cell death regulators such as TAK1, RIPK3 and Caspase 8 gave us insight in the role of endothelial cell death in these pathological models. For example, increased endothelial necroptosis along with basal inflammation in lungs of TAK1ECKO mice affects susceptibility to LPS-induced sepsis and mortality, which correlated with elevated IFN-gamma and MIP-2 serum levels. Furthermore, we found that inhibition of RIPK3-mediated endothelial necroptosis could reduce the susceptibility of TAK1ECKO mice to LPS-induced sepsis and mortality. In ischemia or ischemia-reperfusion models, inhibition of RIPK3-mediated endothelial necroptosis did not reduce injury in the heart after ischemia, nor did it have any effect on organ function post-injury in the kidney or the heart. Inhibition of necroptosis also did not alter vascularization processes in hindlimb post-ischemia. Taken together, endothelial necroptosis contributes to increased sepsis severity and progression whereas inhibition of endothelial necroptosis can ameliorate susceptibility to sepsis in the absence of endothelial TAK1. Inhibition of endothelial necroptosis however does not play an important role during ischemia or ischemia-reperfusion induced organ injury.
Metabolites such as lactate and free fatty acids (FFAs) abundantly occur in high concentrations in tumor and stromal cells of solid malignancies. Their known functions comprise the allocation of nutrients and intermediates for the generation of cell components, the evasion of immune destruction, the induction of vessel formation and the stimulation of cell migration in order to promote tumor growth, progression and metastasis. However, the role of metabolites as signaling molecules and the downstream mechanisms of metabolite receptor mediated signaling in tumor and stromal cells is poorly understood. Our study confirms the expression of Hydroxycarboxylic acid receptor 1 (HCA1) in solid human breast tumors and the expression of Free fatty acid receptor 4 (FFA4) in solid human colorectal tumors. In addition, the expression of HCA1 in human breast cancer cell lines as well as the expression of FFA4 in human colorectal cancer cell lines was proved. Moreover, our research reveals the expression HCA2, FFA2 and FFA4 in tumor associated macrophages (TAMs).
To test whether the loss of any of the metabolite receptors affects tumor growth and progression we utilized a syngeneic Lewis lung cancer (LLC1) tumor model, an azoxymethane (AOM) – dextran sulfate (DSS) colorectal cancer model and a Mouse mammary tumor virus Polyoma Virus middle T antigen (MMTV-PyMT) breast cancer model. The loss of HCA2 did not lead to a changed outcome compared to wild type littermates in any of the models. Likewise, the deletion of FFA4 had no influence on the LLC1 model and, surprisingly, tumor number and area in the AOM-DSS model also remained unaltered. The impact of HCA1 deficiency was investigated utilizing the MMTV-PyMT model and revealed a moderately improved tumor growth. The absence of FFA2 did not affect tumor growth in the LLC1 model but led to an increased number of colorectal tumors in the AOM-DSS model while the tumor area remained unchanged. The most compelling results were obtained upon the deletion of FFA2 in the MMTV-PyMT model. Here, we demonstrate that the loss of FFA2 significantly reduces tumor latency and also significantly improves tumor growth. Nevertheless, the formation of metastases in the LLC1 model and the MMTV-PyMT model did not show any changes upon the loss of any of the metabolite receptors.
Together, our results describe a tumor-protective effect of FFA2 with an unclear impact on metastatic processes. Considerations about putative mechanisms of short chain fatty acid (SCFA) mediated FFA2 signaling suggest potential targets for pharmacological interventions to treat mammary tumors.
Hypertension is a primary risk factor for cardiovascular diseases including myocardial infarction and stroke. Major determinants of blood pressure are vasodilatory factors such as nitric oxide (NO) released from the endothelium under the influence of fluid shear stress exerted by the flowing blood. Defects in flow-induced NO formation go along with endothelial dysfunction, initiation and progression of atherosclerosis as well as with arterial hypertension. Previous work has identified several mechanotransducing signaling processes involved in fluid shear stress-induced endothelial effects. But how fluid shear stress initiates the response is poorly understood. Here, I show in human and bovine endothelial cells that the G-protein Gq/G11 and the purinergic receptor P2Y2 mediate fluid shear stress-induced endothelial responses such as Ca2+ release, nitric oxide (NO) formation and the phosphorylation of platelet-endothelial-cell-adhesion-molecule-1 (PECAM-1), vascular endothelial growth factor-2 (VEGFR-2) and Akt kinase as well as activation of the endothelial NO synthase (eNOS). P2Y2 receptor is activated by adenosine triphosphate (ATP) which is released from endothelial cells under the influence of fluid shear stress. Arteries with P2Y2 or Gαq/Gα11 deficiency have impaired flow-induced dilatation. Mice with induced endothelium-specific deficiency of P2Y2 or Gαq/Gα11 develop hypertension which is accompanied by reduced eNOS activation. My data identify P2Y2 and Gq/G11 as a critical endothelial mechano-signaling pathway located upstream of mechanotransducing processes described so far. Moreover, I demonstrate that P2Y2 and Gq/G11 are required for basal endothelial NO formation, vascular tone and blood pressure.
G-protein-coupled receptors (GPCRs) comprise the largest transmembrane receptor family encoded in the human genome. GPCRs mediate the effect of a wide diversity of stimuli including light, odorants, ions, lipids, small peptides, and hormones. GPR182 is a GPCR for which no endogenous ligand has been identified yet. In the absence of an identified ligand, GPR182 remained poorly understood, and its biological functions had remained elusive. The presented work shows that GPR182 is highly and specifically expressed in microvascular endothelial cells. Phylogenetically, GPR182 is closely related to the atypical chemokine receptor 3 (ACKR3). Here, I show that GPR182 binds the chemokines CXCL10, -12 and -13. Similarly to other so-called atypical chemokine receptors, GPR182 is not coupled to G-proteins but is rather constitutively internalized following β-arrestin 2 recruitment. Consistent with potential scavenger functions, we detected increased concentration of the chemokines which bind the receptor in the plasma of Gpr182 deficient mice. Finally, we show that GPR182 plays an essential role in maintaining hematopoietic stem cells within the bone marrow niche. In summary, the data indicate that GPR182 is a novel member of the group of atypical chemokine receptors, which plays an important role in the chemokine/chemokine receptor network.
Inflammation is a crucial host defense mechanism activated in response to injury or infection. Its primary goal is to eliminate the source of the disturbance, repair the damaged tissue, and restore homeostasis. Inflammatory processes can be recognized through increased blood flow, higher vascular permeability, and the recruitment of leukocytes and plasma proteins to the tissue. A pathogen-induced inflammation triggers various pro- and anti-inflammatory processes. Local tissue cells and Toll-like receptors call upon innate immune cells like neutrophils, dendritic cells (DCs), and monocytes to respond to the intruder. They move across the endothelium and respond to local signals by releasing mediators or cytotoxic compounds, phagocytosing, or polarizing. To study local pathogen-induced inflammation, a zymosan-induced inflammation model was used in the hind paws of mice, which caused a Toll-like receptor 2 mediated inflammation. Multi-Epitope-Ligand-Cartography (MELC) was used for multiple sequential immunohistochemistry with 40 different antibodies on the same tissue. Bioinformatic analysis and graphical representation revealed a specific inflammatory architecture consisting of three major areas based on macrophage polarization and their cellular neighborhoods: a core region containing the pathogen, a pro-inflammatory region containing M1-like macrophages, and a region containing anti-inflammatory cells. This discovery highlights the coexistence of pro- and antiinflammatory processes during an ongoing inflammation and challenges the concept of a gradual temporal transition from pro- to anti-inflammation. Flow cytometry of the whole paw was performed to support and refine the MELC results. Eosinophils were used as a specific immune cell population to investigate their role in the inflammatory structure. They were found to be present in all three inflammatory regions, adapting their cytokine profile according to their localization. Depleting eosinophils reduced Interleukin 4 (IL-4)- levels, increased edema formation, and mechanical and thermal hypersensitivities during inflammation resolution. In the absence of eosinophils, pro- and anti-inflammatory region could not be determined in the inflammatory architecture, neutrophil numbers increased, and efferocytosis and M2-macrophage polarization were reduced. IL-4 administration restored these regions, normalized neutrophil numbers, efferocytosis, M2-macrophage polarization, and resolution of zymosan-induced hypersensitivity. The results show that eosinophils expressing IL-4 support the resolution of inflammation by enabling the development of an anti-inflammatory framework that encloses pro-inflammatory regions.